PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,110.00
Bid: 12,086.00
Ask: 12,088.00
Change: -56.00 (-0.46%)
Spread: 2.00 (0.017%)
Open: 12,186.00
High: 12,198.00
Low: 12,068.00
Prev. Close: 12,166.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Work-from-home guidance and face masks can be back in winter in UK

Mon, 13th Sep 2021 11:19

(Alliance News) - Guidance to work from home and the mandatory use of face masks are likely to be retained as options in the Covid winter plan due to be set out by UK Prime Minister Boris Johnson.

The prime minister will tell the nation on Tuesday how the country can learn to live with the virus, underlining how vaccinations will be a central part of the response to coronavirus in the coming months.

Covid laws that are no longer required will be ditched and plans for vaccine passports for nightclubs and other large crowd venues have been shelved.

The travel traffic lights system is also expected to be scrapped and PCR tests will no longer be required for fully vaccinated travellers.

Speaking on Monday, Work & Pensions Secretary Therese Coffey said some regulations may still be needed as the NHS prepares to battle both Covid and seasonal flu in the winter months.

Asked about maintaining the work-from-home advice, she told BBC Breakfast of the need to keep some rules on the table, adding: "Whether that's with what you just mentioned or making sure statutory sick pay can be paid from day one rather than day four, as tends to happen in more regular times.

"These are the sensible measures I think that we're going to keep."

On the issue of masks, she added: "The prime minister will be setting out the Covid winter plan tomorrow. I think my approach, and I see that with a lot of employers' organisations, is about having a situation-specific approach."

It comes after Health Secretary Sajid Javid said on Sunday that vaccine passports were a "huge intrusion into people's lives" and there were no current plans to go ahead with them.

He said: "You have got to be really, really certain that's what you want to do. We have looked at it and whilst we will keep it in reserve I am pleased to say that we will not be going ahead."

However, Coffey said the introduction of vaccine passports had not been "ruled out forever".

She said: "As Sajid Javid set out yesterday, although the formal decision is still to be made, but having reflected and looked at the details of the proposal that it's not deemed necessary at this moment in time.

"But they haven't been ruled out forever. It's reflecting the fact that a lot of young people have come forward and got their vaccinations over the summer."

The government has yet to set out the plans for booster vaccinations, which are expected to be given to the most vulnerable people first.

A decision has also not yet been made by the UK's chief medical officers on extending the Covid vaccination programme to healthy 12 to 15-year-olds.

The Joint Committee on Vaccination & Immunisation has already said the margin of benefit is considered too small to support universal vaccination of healthy youngsters at this time.

Elsewhere, Neil Ferguson, whose modelling was instrumental to the UK going into lockdown in March 2020, has said he is in favour of a booster programme.

The scientist, from Imperial College London, and a member of the Scientific Advisory Group for Emergencies, told BBC Radio 4's Today programme on Monday that in the absence of social distancing measures, which he did agree with, "we are reliant on immunity building up in the population".

He added: "That happens two ways – one through vaccination, and one through people getting infected and so the faster we can roll our additional vaccination, the better in terms of stopping people getting severely ill but also in reducing transmission."

He said the UK had been leading in Europe on vaccination until recently but other countries such as Spain, Portugal, France, Italy and Ireland "have got higher vaccination levels than us and that's largely because they have rolled out vaccination of 12 to 15-year-olds faster than us.

"They also vaccinated more recently, and we know now that vaccine effectiveness decays over time, we always expected that, and so they have more immunity in the population.

"They also principally used the Pfizer vaccine which against Delta is somewhat more effective than the AstraZeneca vaccine, so there are a set of countries in Europe with considerably more population immunity than us and I think if we want to stop the risk of the large autumn and winter wave we need to boost immunity in the population."

Ferguson said vaccinating teenagers with a first shot was the priority as the UK looks at dealing with any autumn and winter surges in Covid. But he said evidence from Israel suggested booster shots for a wider population were "very effective at further driving down transmission and infection".

Asked whether a further lockdown could be ruled out, he said "I hope so" but added that "you can't rule out anything completely".

The issue of vaccine passports has caused growing disquiet among Tory ranks, as well as facing opposition from opposition parties and industry figures.

The decision not to implement them means measures in England deviate from those in Scotland, where a motion on their introduction was passed in the Scottish Parliament on Thursday, while a decision is expected in Wales next week.

Stormont ministers have yet to reach an official position on using vaccine access passports within Northern Ireland.

By Jane Kirby and Sam Blewett

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
22 Dec 2023 07:17

AstraZeneca gets FDA green light for nerve disease treatment

(Sharecast News) - The US Food and Drug Administration has approved the Wainua nerve disease treatment jointly developed by AstraZeneca and Ionis Pharmaceuticals.

Read more
19 Dec 2023 19:56

US adds 13 companies in China to Unverified List

WASHINGTON, Dec 19 (Reuters) - The United States has added 13 companies in China to a list of entities receiving U.S. exports that officials have been unable to inspect, according to a government notice posted on Tuesday.

Read more
15 Dec 2023 17:14

London stocks log weekly gains as cenbank fest ends

FTSE 100 down 1.0%, FTSE 250 off -0.3%

*

Read more
15 Dec 2023 16:51

LONDON MARKET CLOSE: FTSE 100 underperforms as post-Fed rally cools

(Alliance News) - London's FTSE 100 ended lower on Friday, with profit-taking and some hawkish words from a US policymaker keeping equities in check at the end of a largely positive week for stocks.

Read more
15 Dec 2023 16:29

PRESS: GSK, Astra and AbbVie in US scrutiny over patents - Bloomberg

(Alliance News) - A US senator has accused AstraZeneca PLC, GSK PLC, AbbVie Inc and other drugmakers of "abusing" the patent system to send prices higher, Bloomberg reported on Thursday.

Read more
13 Dec 2023 17:07

UK's FTSE 100 rises as pound slips on GDP data; awaits Fed rate decision

UK economy shrinks by 0.3% in October

*

Read more
12 Dec 2023 16:00

London close: Stocks slip as investors digest US inflation

(Sharecast News) - London's markets finished in the red on Tuesday, as investors digested a slight decrease in consumer inflation in the US, while the UK's unemployment figures remained stable.

Read more
12 Dec 2023 12:07

London midday: FTSE still firmer ahead of US inflation print

(Sharecast News) - London's markets remained relatively stable by midday on Tuesday, with the top-flight index still in the green after fresh jobs data showed a slowdown in wage growth.

Read more
12 Dec 2023 10:08

AstraZeneca buys respiratory vaccine developer Icosavax in $1.1 bln deal

Dec 12 (Reuters) - AstraZeneca said on Tuesday it had agreed to buy respiratory syncytial virus (RSV) vaccine developer Icosavax in a deal valued at up to $1.1 billion.

Read more
12 Dec 2023 08:53

LONDON MARKET OPEN: FTSE 100 opens higher ahead of US CPI

(Alliance News) - Stock prices in London opened higher on Tuesday, as investors digest the latest UK unemployment data, before turning their eyes to US inflation this afternoon.

Read more
12 Dec 2023 08:37

AstraZeneca acquires vaccine developer Icosavax for USD1.1 billion

(Alliance News) - AstraZeneca PLC confirmed on Tuesday that it will buy Icosavax Inc, boosting its vaccine portfolio with an "innovative" treatment for respiratory viruses.

Read more
12 Dec 2023 07:39

LONDON BRIEFING: UK unemployment unchanged at 4.2%; eyes on US CPI

(Alliance News) - Stocks in London are called to open higher, as investors digest the latest UK unemployment data, before turning their heads to US inflation.

Read more
12 Dec 2023 07:16

AstraZeneca to buy US vaccine maker Icosavax for up to $1.1bn

(Sharecast News) - AstraZeneca said on Tuesday that it has agreed to buy Icosavax - a US-based clinical-stage biopharmaceutical company - for up to $1.1bn.

Read more
12 Dec 2023 02:00

UK companies pause China investment decisions as economy slows, survey shows

BEIJING, Dec 12 (Reuters) - A slowdown in both the Chinese and global economies is the biggest issue affecting British firms in the world's second-largest economy, beating geopolitical concerns and market access barriers, according to the British Chamber of Commerce in China.

Read more
11 Dec 2023 08:15

AstraZeneca says danicopan tests well as blood disorder treatment

(Alliance News) - AstraZeneca PLC on Monday reported "positive results" from a test of danicopan for the treatment of paroxysmal nocturnal haemoglobinuria, or PNH, a rare and severe blood disorder.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.